Pharmaceuticals & Biotechnology
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Profitability: Very strong Profitability. One year profit margin are 21%.
Balance Sheet: Strong Balance Sheet.
Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.
Technicals: Bullish SharesGuru indicator.
Size: It is among the top 200 market size companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Growth: Good revenue growth. With 32.1% growth over past three years, the company is going strong.
Past Returns: In past three years, the stock has provided 9.9% return compared to 13.3% by NIFTY 50.
Valuation | |
|---|---|
| Market Cap | 59.24 kCr |
| Price/Earnings (Trailing) | 38.1 |
| Price/Sales (Trailing) | 8.46 |
| EV/EBITDA | 27.89 |
| Price/Free Cashflow | 66.09 |
| MarketCap/EBT | 29.48 |
| Enterprise Value | 58.65 kCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 7.11 kCr |
| Rev. Growth (Yr) | 6.4% |
| Earnings (TTM) | 1.52 kCr |
| Earnings Growth (Yr) | 4.2% |
Profitability | |
|---|---|
| Operating Margin | 29% |
| EBT Margin | 29% |
| Return on Equity | 38% |
| Return on Assets | 26.77% |
| Free Cashflow Yield | 1.51% |
Growth & Returns | |
|---|---|
| Price Change 1W | 3% |
| Price Change 1M | 0.80% |
| Price Change 6M | -12.3% |
| Price Change 1Y | -11.8% |
| 3Y Cumulative Return | 9.9% |
| 5Y Cumulative Return | 13.1% |
| 7Y Cumulative Return | 20.6% |
| 10Y Cumulative Return | 18.5% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | 182.18 Cr |
| Cash Flow from Operations (TTM) | 1.01 kCr |
| Cash Flow from Financing (TTM) | -925.17 Cr |
| Cash & Equivalents | 591.1 Cr |
| Free Cash Flow (TTM) | 959.24 Cr |
| Free Cash Flow/Share (TTM) | 451.42 |
Balance Sheet | |
|---|---|
| Total Assets | 5.69 kCr |
| Total Liabilities | 1.68 kCr |
| Shareholder Equity | 4.01 kCr |
| Current Assets | 3.87 kCr |
| Current Liabilities | 1.41 kCr |
| Net PPE | 308.8 Cr |
| Inventory | 937.86 Cr |
| Goodwill | 0.00 |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.00 |
| Debt/Equity | 0.00 |
| Interest Coverage | 88.19 |
| Interest/Cashflow Ops | 69.6 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 475 |
| Dividend Yield | 1.73% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.00% |
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Profitability: Very strong Profitability. One year profit margin are 21%.
Balance Sheet: Strong Balance Sheet.
Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.
Technicals: Bullish SharesGuru indicator.
Size: It is among the top 200 market size companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Growth: Good revenue growth. With 32.1% growth over past three years, the company is going strong.
Past Returns: In past three years, the stock has provided 9.9% return compared to 13.3% by NIFTY 50.
Investor Care | |
|---|---|
| Dividend Yield | 1.73% |
| Dividend/Share (TTM) | 475 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 717.23 |
Financial Health | |
|---|---|
| Current Ratio | 2.74 |
| Debt/Equity | 0.00 |
Technical Indicators | |
|---|---|
| RSI (14d) | 61.25 |
| RSI (5d) | 78.5 |
| RSI (21d) | 55.09 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Sell |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal | Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
Updated May 5, 2025
Despite positive aspects, Abbott India has seen a decline in mutual fund and foreign institutional investor holdings, with current holdings at 7.73% and 0.16%, respectively.
The stock has experienced a 5-day decline of 1.59% and a monthly drop of 1.52%, suggesting some volatility.
The company has a vacant Chief Financial Officer position, which may raise concerns about its management stability.
Abbott India has a strong analyst backing with three recommending a strong buy and two a buy, indicating confidence in its stock.
The company reported a significant net profit of Rs 360.78 Crores in the last quarter, showcasing its financial health.
Abbott India continues to innovate and expand its product offerings, especially in therapeutic areas like women's health and gastroenterology.
This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.
Summary of Abbott India's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Understand Abbott India ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| ABBOTT CAPITAL INDIA LIMITED | 50.44% |
| ABBOTT HEALTHCARE PRODUCTS LIMITED | 17.62% |
| BRITISH COLLOIDS LIMITED | 6.92% |
| SBI LARGE & MIDCAP FUND | 2.66% |
| CANARA ROBECO MUTUAL FUND | 1.1% |
Distribution across major stakeholders
Distribution across major institutional holders
Detailed comparison of Abbott India against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 4.32 LCr | 58.94 kCr | +5.60% | +11.50% | 39.55 | 7.33 | - | - |
| DIVISLAB | Divi's Lab | 1.68 LCr | 10.75 kCr | +4.50% | +13.60% | 67.78 | 15.63 | - | - |
| DRREDDY | Dr. Reddy's Lab | 1.09 LCr | 36.09 kCr | +5.10% | +14.40% | 19.5 | 3.02 | - | - |
| CIPLA | Cipla | 1.07 LCr | 29.37 kCr | -0.40% | -9.60% | 23.47 | 3.63 | - | - |
| AUROPHARMA | Aurobindo Pharma | 71.55 kCr | 33.73 kCr | +1.60% | +10.50% | 20.52 | 2.12 | - | - |
| PFIZER | Pfizer | 22.19 kCr | 2.67 kCr | +2.20% | +18.00% | 25.99 | 8.3 | - | - |
| SANOFI | Sanofi India | 8.71 kCr | 1.86 kCr | -6.20% | -29.90% | 26.67 | 4.69 | - | - |
Comprehensive comparison against sector averages
ABBOTINDIA metrics compared to Pharmaceuticals
| Category | ABBOTINDIA | Pharmaceuticals |
|---|---|---|
| PE | 38.10 | 34.64 |
| PS | 8.46 | 4.78 |
| Growth | 12.5 % | 10.8 % |
Abbott India is a prominent pharmaceuticals company operating in India, identified by the stock ticker ABBOTINDIA. It boasts a significant market capitalization of Rs. 58,957.7 Crores.
The company, founded in 1910 and headquartered in Mumbai, India, focuses on a diverse range of pharmaceutical products, including areas such as:
Abbott India offers solutions for conditions like insomnia, vitamin D deficiency, pre-term labor, and pain management. Their extensive product line also includes anti-infective, cardio-diabetes, hepatology, hormonal, neuro-psychiatry, and consumer care products.
With a trailing 12-month revenue of Rs. 6,323.5 Crores, Abbott India has demonstrated strong financial performance. Over the past year, the company achieved a profit of Rs. 1,286.8 Crores and showcased a remarkable revenue growth of 30.9% over the last three years.
Investors are also rewarded through dividends, with a yield of 2.65% per year and a return of Rs. 735 dividend per share in the last twelve months. Abbott India operates as a subsidiary of Abbott Capital India Limited and emphasizes profitability and consistent growth in the pharmaceutical sector.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
ABBOTINDIA vs Pharmaceuticals (2021 - 2026)